MOSCOW (MRC) -- BASF, the world's largest petrochemical major, and Poietis, the first company in the world for 3D laser-assisted bioprinting, have signed an agreement on research and development in cosmetics, reported BASF on its site.
Based on the combined expertise of both companies in tissue engineering and bioprinting, the agreement aims to apply the bioprinting technology of Poietis to improve BASF’s skin equivalent model Mimeskin. The terms and conditions of this agreement were not disclosed.
The 3D laser-assisted bioprinting technology, by which organic tissues can be reproduced, allows for a precise positioning of the skin cells in three-dimensional structures. Through this, cells are cultivated within BASF’s skin model Mimeskin, which is the closest equivalent to the original physiological tissue of human skin. Dr. Fabien Guillemot, Founder and President of Poietis, remarks: "We are extremely pleased about this collaboration. Having long-term expertise in solutions for the dermocosmetics market, BASF understands the benefits of 3D laser-assisted bioprinting compared to conventional cell culture technologies and other bioprinting methods. The partnership also emphasizes bioprinted tissue models as an alternative to animal testing in cosmetics and dermopharmacy."
As MRC said before, in April 2015, BASF developed new ingredients and innovative concepts for the personal care market. Driving forward the development of the brand Care CreationsTM, the company is taking a more and more science based approach to explore consumer needs: the focus is on a validated typology system with which users can define different consumer personalities.
BASF is the leading chemical company. It produces a wide range of chemicals, for example solvents, amines, resins, glues, electronic-grade chemicals, industrial gases, basic petrochemicals and inorganic chemicals. The most important customers for this segment are the pharmaceutical, construction, textile and automotive industries.
MRC